SNIPR publishes final Phase 1 results for SNIPR001

Final results of the randomized, placebo-controlled, double-blind Phase 1 trial of oral SNIPR001 in healthy volunteers were published in The Lancet Microbe. The trial evaluated safety and tolerability after twice-daily dosing for seven days; no serious adverse events were reported in SNIPR001 dose groups, and gut microbiota composition did not significantly differ from placebo.